The role of non-viral antigens in the cotton rat model of respiratory syncytial virus vaccine-enhanced disease (Q45353912)

13 December 2017

The role of non-viral antigens in the cotton rat model of respiratory syncytial virus vaccine-enhanced disease (English)

1 reference

13 December 2017

9

Philip R Dormitzer

1 reference

13 December 2017

Christine A Shaw

1

1 reference

13 December 2017

Jean-Rene Galarneau

2

1 reference

13 December 2017

Kathryn E Bowenkamp

3

1 reference

13 December 2017

Kurt A Swanson

4

1 reference

13 December 2017

Gene A Palmer

5

1 reference

13 December 2017

Giuseppe Palladino

6

1 reference

13 December 2017

Judit E Markovits

7

1 reference

13 December 2017

Nicholas M Valiante

8

1 reference

13 December 2017

Gillis R Otten

10

1 reference

13 December 2017

language of work or name

English

0 references

publication date

12 November 2012

1 reference

13 December 2017

1 reference

13 December 2017

31

1 reference

13 December 2017

2

1 reference

13 December 2017

306-312

1 reference

Global burden of acute lower respiratory infections due to respiratory syncytial virus in young children: a systematic review and meta-analysis

13 December 2017

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.11.006

Respiratory syncytial virus disease in infants despite prior administration of antigenic inactivated vaccine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.11.006

Field evaluation of a respiratory syncytial virus vaccine and a trivalent parainfluenza virus vaccine in a pediatric population

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.11.006

An epidemiologic study of altered clinical reactivity to respiratory syncytial (RS) virus infection in children previously vaccinated with an inactivated RS virus vaccine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.11.006

Respiratory virus immunization. I. A field trial of two inactivated respiratory virus vaccines; an aqueous trivalent parainfluenza virus vaccine and an alum-precipitated respiratory syncytial virus vaccine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.11.006

Vaccine-enhanced respiratory syncytial virus disease in cotton rats following immunization with Lot 100 or a newly prepared reference vaccine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.11.006

Immune response to experimentally induced infection with respiratory syncytial virus: possible role in the development of pulmonary disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.11.006

Mechanism of lung injury in cotton rats immunized with formalin-inactivated respiratory syncytial virus

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.11.006

Enhanced pulmonary pathology associated with the use of formalin-inactivated respiratory syncytial virus vaccine in cotton rats is not a unique viral phenomenon

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.11.006

Both immunisation with a formalin-inactivated respiratory syncytial virus (RSV) vaccine and a mock antigen vaccine induce severe lung pathology and a Th2 cytokine profile in RSV-challenged mice

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.11.006

Comparison of the ability of formalin-inactivated respiratory syncytial virus, immunopurified F, G and N proteins and cell lysate to enhance pulmonary changes in Balb/c mice

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.11.006

Structural basis for immunization with postfusion respiratory syncytial virus fusion F glycoprotein (RSV F) to elicit high neutralizing antibody titers

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.11.006

The TLR4 agonist, monophosphoryl lipid A, attenuates the cytokine storm associated with respiratory syncytial virus vaccine-enhanced disease.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.11.006

A potential molecular mechanism for hypersensitivity caused by formalin-inactivated vaccines

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.11.006

Lack of antibody affinity maturation due to poor Toll-like receptor stimulation leads to enhanced respiratory syncytial virus disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.11.006

Secreted respiratory syncytial virus G glycoprotein induces interleukin-5 (IL-5), IL-13, and eosinophilia by an IL-4-independent mechanism.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.11.006

Pulmonary histopathology induced by respiratory syncytial virus (RSV) challenge of formalin-inactivated RSV-immunized BALB/c mice is abrogated by depletion of CD4+ T cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.11.006

7 January 2021

Enhanced pulmonary histopathology induced by respiratory syncytial virus (RSV) challenge of formalin-inactivated RSV-immunized BALB/c mice is abrogated by depletion of interleukin-4 (IL-4) and IL-10.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.11.006

7 January 2021

Respiratory syncytial virus infection in inbred mice

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.11.006

7 January 2021

Enhancement of respiratory syncytial virus pulmonary pathology in cotton rats by prior intramuscular inoculation of formalin-inactiva ted virus

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.11.006

7 January 2021

10.1016/J.VACCINE.2012.11.006

Identifiers

DOI

1 reference

13 December 2017

1 reference